Published • loading... • Updated
Regeneron and CytomX extend cancer therapy partnership to $4bn deal
Summary by Pharmaceutical Business Review
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Verdict HospitalReposted by 
Pharmaceutical Business review
Pharmaceutical Business reviewRegeneron and CytomX extend cancer therapy partnership to $4bn deal
Regeneron Pharmaceuticals and CytomX have expanded their research and licensing partnership to develop conditionally activated bispecific antibody cancer therapies.The post Regeneron and CytomX extend cancer therapy partnership to $4bn deal appeared first on Hospital Management.
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
